secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001558370-25-010658
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia Q2 net loss $4.0M; cash $17.6M; DA-1726 48mg data expected Q4 2025
--------------------------------------------------------------------------

- Net loss $4.0M ($0.26/sh) vs $10.1M ($1.85/sh) in Q2 2024; R&D expenses fell to $2.3M from $8.1M.
- Cash $17.6M as of June 30, 2025, expected to fund operations into 2026.
- Dosed first patient in 8-week 48mg MAD cohort of DA-1726 for obesity; top-line data due Q4 2025.
- Signed AI collaboration with Syntekabio to identify new indications for DA-1241 beyond MASH.
- Closed $10.0M private placement in May 2025 with Dong-A ST and Dong-A Socio Holdings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837025010658/0001558370-25-010658-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837025010658/mtva-20250807x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-010658

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer